These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 35458721)
1. Advances in the Development of SARS-CoV-2 Mpro Inhibitors. Agost-Beltrán L; de la Hoz-Rodríguez S; Bou-Iserte L; Rodríguez S; Fernández-de-la-Pradilla A; González FV Molecules; 2022 Apr; 27(8):. PubMed ID: 35458721 [TBL] [Abstract][Full Text] [Related]
2. An automated positive selection screen in yeast provides support for boron-containing compounds as inhibitors of SARS-CoV-2 main protease. Sigurdardóttir S; Silva SF; Tiukova I; Alalam H; King RD; Grøtli M; Eriksson LA; Sunnerhagen P Microbiol Spectr; 2024 Oct; 12(10):e0124924. PubMed ID: 39162260 [TBL] [Abstract][Full Text] [Related]
3. Biflavonoids from Lokhande K; Nawani N; K Venkateswara S; Pawar S J Biomol Struct Dyn; 2022 Jul; 40(10):4376-4388. PubMed ID: 33300454 [TBL] [Abstract][Full Text] [Related]
4. Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions. Shawky AM; Almalki FA; Alzahrani HA; Abdalla AN; Youssif BGM; Ibrahim NA; Gamal M; El-Sherief HAM; Abdel-Fattah MM; Hefny AA; Abdelazeem AH; Gouda AM Eur J Med Chem; 2024 Nov; 277():116704. PubMed ID: 39121741 [TBL] [Abstract][Full Text] [Related]
5. Identification of potent COVID-19 main protease inhibitors by loading of favipiravir on Mg Al-Shuaeeb RAA; Abd El-Mageed HR; Ahmed SA; Mohamed HS; Hamza ZS; Rafi MO; Rahman MS J Biomol Struct Dyn; 2023; 41(21):11437-11449. PubMed ID: 36591698 [TBL] [Abstract][Full Text] [Related]
6. Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Shitrit A; Zaidman D; Kalid O; Bloch I; Doron D; Yarnizky T; Buch I; Segev I; Ben-Zeev E; Segev E; Kobiler O Sci Rep; 2020 Nov; 10(1):20808. PubMed ID: 33257760 [TBL] [Abstract][Full Text] [Related]
15. Catechin Derivatives as Inhibitor of COVID-19 Main Protease (Mpro): Molecular Docking Studies Unveil an Opportunity Against CORONA. Arif MN Comb Chem High Throughput Screen; 2022; 25(1):197-203. PubMed ID: 33231155 [TBL] [Abstract][Full Text] [Related]
16. Antiviral peptides inhibiting the main protease of SARS-CoV-2 investigated by computational screening and in vitro protease assay. Stewart J; Shawon J; Ali MA; Williams B; Shahinuzzaman ADA; Rupa SA; Al-Adhami T; Jia R; Bourque C; Faddis R; Stone K; Sufian MA; Islam R; McShan AC; Rahman KM; Halim MA J Pept Sci; 2024 Apr; 30(4):e3553. PubMed ID: 38031661 [TBL] [Abstract][Full Text] [Related]
17. Discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 via virtual screening and biochemical evaluation. Guo S; Xie H; Lei Y; Liu B; Zhang L; Xu Y; Zuo Z Bioorg Chem; 2021 May; 110():104767. PubMed ID: 33667900 [TBL] [Abstract][Full Text] [Related]
18. Isatin-based virtual high throughput screening, molecular docking, DFT, QM/MM, MD and MM-PBSA study of novel inhibitors of SARS-CoV-2 main protease. Varadharajan V; Arumugam GS; Shanmugam S J Biomol Struct Dyn; 2022 Oct; 40(17):7852-7867. PubMed ID: 33764269 [TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M Ghosh A; Chakraborty M; Chandra A; Alam MP J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023 [TBL] [Abstract][Full Text] [Related]
20. Investigating the antiviral therapeutic potentialities of marine polycyclic lamellarin pyrrole alkaloids as promising inhibitors for SARS-CoV-2 and Zika main proteases (Mpro). Pereira F; Bedda L; Tammam MA; Alabdullah AK; Arafa R; El-Demerdash A J Biomol Struct Dyn; 2024 May; 42(8):3983-4001. PubMed ID: 37232419 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]